The pathogenesis of Alzheimer's disease is very complex, and there is a lack of clinically effective cures or drugs. The reporter learned from the Kunming Institute of Botany of the Chinese Academy of Sciences on the 19th that Chinese researchers recently discovered for the first time that limonoid compounds may be used as lead compounds for the treatment of Alzheimer's disease, which provides new ideas for the research and development of new drugs.
Alzheimer's disease, also known as Alzheimer's disease, is the most common neurodegenerative disease that occurs in old age. At present, our country has the largest group of patients with such diseases in the world, and their care and treatment bring a heavy burden to families and society. In recent years, the exploration of potential new drug targets for Alzheimer's disease and the development of drugs that act on potential new drug targets have been the directions explored by major pharmaceutical companies and scientific research institutes. In our country, strengthening preventive intervention for elderly disability and Alzheimer's disease has been listed as a major task to comprehensively promote the construction of a healthy China during the 14th Five-Year Plan period.
Previously, the research group of Academician Hao Xiaojiang of the Phytochemical Biology Team of the Kunming Institute of Botany, Chinese Academy of Sciences, has long been committed to the discovery of plant-derived anti-Alzheimer's active substances, and has achieved a series of results, such as cooperation with Kunming Animal Cai Jingxia's research group at the Institute collaborated with Fencrodone, which has entered Phase II clinical trials; and Yang Chonglin's research group at the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, discovered important active lead compounds ingenol esters that can promote lysosome production, etc. . Recently, Hao Xiaojiang's research group collaborated with Yao Yonggang's research group of our institute and discovered a novel limonoid compound in the plant Quasimarinaceae, and its structure was finally confirmed through X-ray single crystal diffraction experiments. Using Western blotting technology, enzyme-linked immunosorbent assay and cell transcriptome sequencing analysis, it was found that this compound can act through multiple targets. This innovative discovery may bring about a turning point in the future development of new drugs for Alzheimer's disease. The relevant results were published as a cover article in the authoritative organic chemistry journal "Organic Chemistry Letters" and have applied for invention patent protection.